Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCapital International Ltd /ca/
Latest Disclosed Ownership95,874 shares
Latest Disclosed Value $ 42,811,576
Capital International Ltd /ca/ reports 0.27% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 13, 2026 - Capital International Ltd /ca/ filed a 13F-HR form disclosing ownership of 95,874 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $42,811,576 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 95,612 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.27% during the quarter. The current value of the position is $42,839,379 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 95,874 262 0.27 42,812 -1.23 1.5867
2026-02-11 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 95,612 -25,675 -21.17 43,347 -8.75 1.5276
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 121,287 -6,320 -4.95 47,501 -16.39 1.7187
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 127,607 15,061 13.38 56,811 4.12 2.1763
2025-05-12 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 112,546 1,975 1.79 54,565 22.54 2.3789
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 110,571 10,966 11.01 44,527 -3.88 1.8162
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 99,605 -866 -0.86 46,324 -1.63 1.9964
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100,471 915 0.92 47,093 13.16 2.1716
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 99,556 14,680 17.30 41,615 20.50 1.9906
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 84,876 3,377 4.14 34,535 21.86 1.7710
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 81,499 1,259 1.57 28,340 0.36 1.6299
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 80,240 10,527 15.10 28,237 28.56 1.5825
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,713 4,258 6.51 21,964 16.20 1.3171
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 65,455 -5,395 -7.61 18,902 -7.86 1.3028
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 70,850 7,483 11.81 20,514 14.89 1.4300
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 63,367 111 0.18 17,856 8.17 1.3438
2022-05-19 2022-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 63,256 -20,335 -24.33 16,508 -10.07 0.9406
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 63,256 -20,335 16,508 0.9498
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 83,591 10,036 13.64 18,357 37.59 0.9324
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 73,555 -12,473 -14.50 13,342 -23.08 0.7264
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 86,028 6,144 7.69 17,346 1.05 0.9556
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 79,884 -1,275 -1.57 17,166 -10.51 1.0361
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 81,159 -1,091 -1.33 19,181 -14.30 1.1198
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 82,250 16,221 24.57 22,382 16.76 1.5168
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 66,029 3,004 4.77 19,169 27.82 1.7942
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 63,025 63,025 14,997 1.6822
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 0 -6,831 -100.00 0 -100.00
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 6,831 797 13.21 1,161 18.11 0.2030
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 6,034 6,034 983 0.1761
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.